Literature DB >> 1467511

Cytokine dysregulation and acute graft-versus-host disease.

J H Antin1, J L Ferrara.   

Abstract

We suggest that acute GVHD after marrow transplantation reflects (1) host injury due to the conditioning regimen followed by the production of inflammatory cytokines; (2) stimulation of mature donor T cells in the milieu of increased cell surface expression of leukocyte adhesion molecules and HLA molecules, followed by the autocrine production of IL-2; and, finally, (3) recruitment and activation of additional mononuclear effector cells from donor marrow progenitors, which produce additional inflammatory cytokines, thus sustaining the response. The second step is critical for the amplification of the systemic inflammatory response, and it is absence in autologous, syngeneic, and T-cell-depleted transplants. These T cells may also contribute to the inflammatory cytokine network. Acute GVHD can occur in the absence of primary tissue injury in such settings as transfusion-related GVHD; however, it is likely that a greater HLA disparity between donor and host is required. We propose that inflammatory cytokine production is the final common pathway of acute GVHD. If this model is correct, control of cytokine dysregulation at any of several points should control GVHD. Further studies of GVHD and investigations of cytokine antagonists (eg, IL-4 or IL-10) or combinations of antagonists such as IL-1ra and soluble TNF receptor or pentoxifylline will allow us to determine the validity of this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467511

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  121 in total

1.  Hematopoietic stem cell transplantation: current status of old issues.

Authors:  N Kapoor
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

Review 2.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

3.  Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome.

Authors:  D Zoukhri; C L Kublin
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-04       Impact factor: 4.799

Review 4.  Mechanisms involved in injury and repair of the murine lacrimal gland: role of programmed cell death and mesenchymal stem cells.

Authors:  Driss Zoukhri
Journal:  Ocul Surf       Date:  2010-04       Impact factor: 5.033

Review 5.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

Review 6.  Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Authors:  Vikas Gupta; Jason Gotlib; Jerald P Radich; Nicolaus M Kröger; Damiano Rondelli; Srdan Verstovsek; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-27       Impact factor: 5.742

7.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.

Authors:  W S Bartynski; J F Boardman; Z R Zeigler; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

Review 8.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

9.  A high percentage of HLA-DQ+ and HLA-DR+ mononuclear cells is associated with a low incidence of acute graft-versus-host disease after allogeneic bone marrow transplantation (BMT) in children.

Authors:  L Garin; D Rigal; S el Marsafy; J Bernaud; N Philippe; G Souillet
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 10.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.